MacroGenics, Inc. (NASDAQ:MGNX) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Jim Karrels - Senior Vice President and Chief Financial Officer Scott Koenig - President and Chief Executive Officer Conference Call Participants Jonathan Chang - SVB Securities Etzer Darout - BMO Capital Markets David Dai - SMBC Jon Miller - Evercore ISI Stephen Willey - Stifel Boris Peaker - Cowen Silvan Tuerkcan - JMP Securities Operator Good afternoon. We will begin the MacroGenics 2022 Fourth ...

For the transition period from to Commission File Number 001-36112 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 (Exact name of registrant) MACROGENICS, INC. Indicate by check mark if the registrant is a well-known seasoned issuer, as defin ...

MacroGenics, Inc. (NASDAQ:MGNX) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Jim Karrels - SVP and CFO Dr. Scott Koenig - President and CEO Conference Call Participants Jessica Hui - Evercore Jonathan Chang - SVB Securities David Dai - SMBC Charles Zhu - Guggenheim Partners Silvan Tuerkcan - JMP Securities Operator Good afternoon. We will begin the MacroGenics 2022 Third Quarter Corporate Progress and Financial Results Conference Call in just a moment. [Operator Instructi ...

MacroGenics, Inc. (NASDAQ:MGNX) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Chris James - VP, IR and Corporate Communications Scott Koenig - President and CEO Jim Karrels - CFO Conference Call Participants Jon Miller - Evercore ISI David Dai - SMBC Stephen Willey - Stifel Etzer Darout - BMO Capital Markets Faisal Khurshid - SVB Securities Operator Good afternoon. We will begin the MacroGenics' 2022 Second Quarter Corporate Progress and Financial Results Conference Call in ...

For the quarterly period ended June 30, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1591613 (State or other jurisdiction of incorpor ...

MacroGenics, Inc. (NASDAQ:MGNX) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Chris James - Vice President, Investor Relations and Corporate Communications Scott Koenig - President and Chief Executive Officer Jim Karrels - Chief Financial Officer Conference Call Participants Jonathan Chang - SVB Securities Kaveri Pohlman - BTIG Etzer Darout - BMO Capital Markets Peter Lawson - Barclays Stephen Willey - Stifel Jonathan Miller - Evercore ISI Yigal Nochomovitz - Citigroup David D ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1591613 (State or other jurisdiction of incorpo ...

® Developing Breakthrough Biologics, Life-changing Medicines® Corporate Update February 24, 2022 The information in this slide deck is current as of February 24, 2022, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements 2 Legal Notices Any statements in these materials about future expectations, ...

MacroGenics, Inc. (NASDAQ:MGNX) Q4 2021 Results Conference Call February 24, 2022 4:30 PM ET Company Participants Christopher James - Vice President of Investor Relations and Corporate Communications Scott Canning - President and Chief Executive Officer James Karrels - Senior Vice President and Chief Financial Office Conference Call Participants Kaveri Pohlman - BTIG Etzer Darout - BMO Capital Markets Asha Babaric - Citi Charles Zhu - Guggenheim Jonathan Miller - Evercore ISI Stephen Willey - Stifel Silvan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR (301) 251-5172 (Registrant's telephone number) Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common Stock, par value $0.01 per share | MGNX | Nasdaq Global Selec ...